Adverum Biotechnologies, Inc. (ADVM)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| License revenue | - | 1,000 | - | |
| Research and development | 37,125 | 20,439 | 17,097 | |
| General and administrative | 12,730 | 9,782 | 3,785 | |
| Total operating expenses | 49,855 | 30,221 | 20,882 | |
| Operating loss | -49,855 | -29,221 | -20,882 | |
| Other income, net | 664 | - | - | |
| Other income, net | - | 2,087 | 2,406 | |
| Net loss before income taxes | - | -27,134 | -18,476 | |
| Net loss | -49,191 | -27,134 | -18,476 | |
| Net unrealized loss on marketable securities | -11 | 241 | -2 | |
| Foreign currency translation adjustment | 18 | 16 | 10 | |
| Comprehensive loss | -49,184 | -26,877 | -18,468 | |
| Net loss per share basic (in usd per share) | -2.34 | -1.3 | -0.89 | |
| Net loss per share diluted (in usd per share) | -2.34 | -1.3 | -0.89 | |
| Weighted-average common shares used to compute net loss per share - basic (in shares) | 21,010,000 | 20,876,000 | 20,852,000 | |
| Weighted-average common shares used to compute net loss per share - diluted (in shares) | 21,010,000 | 20,876,000 | 20,852,000 | |